Skip to content

Memory & Conditioning Under Anesthesia

Modulation of Memory and Conditioning by Pain During Sedation With Anesthetics

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04062123
Acronym
MCA
Enrollment
92
Registered
2019-08-20
Start date
2020-07-30
Completion date
2024-04-22
Last updated
2025-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia, Pain

Keywords

propofol, dexmedetomidine, fentanyl, functional MRI, electric nerve stimulation, sedation, functional connectivity

Brief summary

The purpose of this study is to determine the effects of pain on long-term memory and conditioned physiologic responses in the presence and absence of distinct intravenous anesthetics. Functional magnetic resonance imaging will be used to identify the neural correlates of these phenomena The study will occur over 5 visits and involves no long-term follow up.

Detailed description

Purpose: Sedative-hypnotic and analgesic agents (termed anesthetics) are routinely used during medical procedures to prevent or ease suffering, suppressing the conscious experience of pain and its encoding into memory. While overt awareness under general anesthesia is a rare clinical event, implicit memory may still form. Further, at sub-hypnotic anesthetic doses, animals show enhanced fear conditioning and humans may have enhanced amygdala activity. This motivates the investigator's study, as poorly-contextualized aversive memories are theorized to initiate anxiety-spectrum disorders, which may explain the high incidence of post-traumatic stress disorder after anesthetic awareness. Objective: How anesthetics facilitate or inhibit poorly-contextualized aversive memories is incompletely understood, with little mechanistic work done in human subjects. Thus, there is a critical need to understand how anesthetics modulate the memory and threat response systems during painful stimulation. The overall scientific objective is to determine the memory-modulating effects of propofol, dexmedetomidine, and fentanyl in the context of periodic painful stimulation. Aim 1: Determine how behavioral and physiologic measures of memory are modulated by pain and the individual effects of three pharmacologically distinct drugs: propofol, dexmedetomidine, and fentanyl. Hypotheses: Based on previous results, 1a) explicit memory will be significantly reduced by propofol and dexmedetomidine, but only modestly by fentanyl. Consistent with my preliminary data, 1b) priming effects will be seen for pain-paired words under all drugs. Electrodermal activity changes still occur with opioids and propofol, thus 1c) pain-related physiologic responses will persist with these two drugs but be blunted by the anti-adrenergic effect of dexmedetomidine. Aim 2: Determine the brain structures differentially engaged in memory encoding under pain and drug conditions. Task-related functional magnetic resonance imaging (MRI) activity for behavioral measures of explicit or implicit memory will be determined, comparing pain-paired vs non-pain items across drug and no-drug datasets. Functional connectivity (FC) MRI (fcMRI) will be compared between task and drug conditions. The entire brain will be explored, but predictions for key structures follow. Hypotheses: 2a) Hippocampal activity, will be blunted by propofol and dexmedetomidine, while fentanyl will have minimal effect. 2b) Amygdala activity, responsible for physiologic responses, will parallel the predictions in 1c across drug and pain conditions. 2c) Insula activity will be greater for pain-paired items, and this will be attenuated by fentanyl \> dexmedetomidine \> propofol, corresponding to their anticipated analgesic effect. 2d) Pain has been shown to affect fcMRI during a cognitive task, and thus FC between the key regions in 2a-c will be reduced by all three drugs, in characteristic patterns.

Interventions

DRUGDexmedetomidine

Subjects in this group will receive a intravenous infusion of this drug, during a portion of the study. Dose will be targeted to a brain effect site concentration of 0.15 ng/ml, using pharmacokinetic modelling within the STANPUMP algorithm that accounts for subject's age, gender, height, & weight.

DRUGPropofol

Subjects in this group will receive a intravenous infusion of this drug, during a portion of the study. Dose will be targeted to a brain effect site concentration of 0.7 mcg/ml, using pharmacokinetic modelling within the STANPUMP algorithm that accounts for subject's age, gender, height, & weight.

DRUGFentanyl

Subjects in this group will receive a intravenous infusion of this drug, during a portion of the study. Dose will be targeted to a brain effect site concentration of 0.9 ng/ml, using pharmacokinetic modelling within the STANPUMP algorithm that accounts for subject's age, gender, height, & weight.

DEVICEPeripheral Nerve Stimulation

Experimental acute pain stimulus will be delivered using a nerve stimulator. These painful shocks will be paired randomly with some of the experimental cues.

DRUGPlacebo

Crystalloid IV solution will be infused, with no active drug.

Sponsors

National Institute of General Medical Sciences (NIGMS)
CollaboratorNIH
Keith M Vogt
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Subject)

Masking description

single-blind

Intervention model description

Placebo-controlled, within-subject, crossover between no-drug and assigned drug (in randomized order)

Eligibility

Sex/Gender
ALL
Age
18 Years to 39 Years
Healthy volunteers
Yes

Inclusion criteria

* Adults, age 18-39, who are native English speakers with at least a high school education * have normal hearing and memory * be of normal body-weight * be generally healthy (free from significant chronic disease) * have none of the specific

Exclusion criteria

* have a valid email address and valid phone number throughout the study * anticipate ability to participate in all visits required for the phase of the study in which they are enrolled

Design outcomes

Primary

MeasureTime frameDescription
Explicit Memory Performance24-hrs post-experimentRecognition memory testing, using the Remember-Know procedure, in which subjects indicate whether they recognize previously experienced experimental items among novel items (not previously in the experiment). This allows calculation of interdependent measures of recollection & familiarity using the signal detection statistic, d'. d' is calculated as the cumulative Gaussian distribution of false positive responses subtracted from the cumulative Gaussian distribution of correctly identified previously-experienced items. d' is on a (theoretically infinite) scale of standard deviation units, with negative values representing performance worse than chance guessing and positive values representing stand deviations of performance above chance.

Secondary

MeasureTime frameDescription
Brain Activation in the Hippocampus for Successful Memory Formation: Placebo Condition Minus Drug ConditionImmediately after each experimental itemThe Z-score is calculated by linear regression of the task timing against the MRI signal time-course (MRI data is in arbitrary units with no maximum or minimum) at each voxel (single data point in brain). The outcome is listed for the hippocampus, but similar scores are calculated throughout the brain. Z-score of 0 indicates no task-related changes. Z-scores further from zero indicate a larger difference in brain activity, with positive values indicating decreases under the drug condition, while negative Z-scores indicate increases under drug, compared to control. This outcome is reported as a number, as it is calculated using all the data across subjects combined into one statistical measure for the overall strength of difference in MRI signal change between two groups of data. Dispersion measures cannot be calculated for the summary Z-score.
Heart Rate ResponseImmediately after each experimental itemHeart rate changes (measured by electrocardiogram, EKG) were planned to be determined following experimental stimuli that delivered as part of the experiment. A 1-6 second window of physiologic data will be analyzed for changes in the peak of the EKG response (R-wave), allowing calculation of instantaneous heart rate. Increases in heart rate are well-known to correlate to sympathetic nervous system activity increases.
Skin ResponseImmediately after each experimental itemElectrodermal activity (galvanic skin) response was planned to be determined following experimental stimuli that delivered as part of the experiment. A 1-6 second window of physiologic data will be analyzed for changes in electrodermal activity, measured from the palm of subjects' hand. this well-established measure indicates sweat gland activity and is correlated to sympathetic nervous system activity increases.

Countries

United States

Participant flow

Participants by arm

ArmCount
Propofol
Subjects in this group received intravenous propofol, during a portion of the study. Dose was targeted to an effect site concentration of 1.0 mcg/ml, using pharmacokinetic modelling that accounts for subject's age, gender, height, & weight.
30
Dexmedetomidine
Subjects in this group received intravenous dexmedetomidine, during a portion of the study. Dose was targeted to an effect site concentration of 0.15 ng/ml, using pharmacokinetic modelling that accounts for subject's age, gender, height, & weight.
29
Fentanyl
Subjects in this group received intravenous fentanyl, during a portion of the study. Dose was targeted to a brain effect site concentration of 0.9 ng/ml, using pharmacokinetic modelling that accounts for subject's age, gender, height, & weight.
33
Total92

Withdrawals & dropouts

PeriodReasonFG000FG001FG002
Overall StudyWithdrawal by Subject010

Baseline characteristics

CharacteristicPropofolTotalFentanylDexmedetomidine
Age, Continuous25.0 years
STANDARD_DEVIATION 6.2
24.8 years
STANDARD_DEVIATION 5.9
23.9 years
STANDARD_DEVIATION 5
25.6 years
STANDARD_DEVIATION 6.5
Ethnicity (NIH/OMB)
Hispanic or Latino
1 Participants7 Participants3 Participants3 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
22 Participants71 Participants27 Participants22 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
7 Participants14 Participants3 Participants4 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
5 Participants19 Participants8 Participants6 Participants
Race (NIH/OMB)
Black or African American
0 Participants3 Participants3 Participants0 Participants
Race (NIH/OMB)
More than one race
0 Participants6 Participants4 Participants2 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
7 Participants14 Participants3 Participants4 Participants
Race (NIH/OMB)
White
18 Participants50 Participants15 Participants17 Participants
Region of Enrollment
United States
30 participants92 participants33 participants29 participants
Sex: Female, Male
Female
14 Participants45 Participants16 Participants15 Participants
Sex: Female, Male
Male
16 Participants47 Participants17 Participants14 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
0 / 300 / 290 / 33
other
Total, other adverse events
0 / 300 / 292 / 33
serious
Total, serious adverse events
0 / 300 / 290 / 33

Outcome results

Primary

Explicit Memory Performance

Recognition memory testing, using the Remember-Know procedure, in which subjects indicate whether they recognize previously experienced experimental items among novel items (not previously in the experiment). This allows calculation of interdependent measures of recollection & familiarity using the signal detection statistic, d'. d' is calculated as the cumulative Gaussian distribution of false positive responses subtracted from the cumulative Gaussian distribution of correctly identified previously-experienced items. d' is on a (theoretically infinite) scale of standard deviation units, with negative values representing performance worse than chance guessing and positive values representing stand deviations of performance above chance.

Time frame: 24-hrs post-experiment

ArmMeasureValue (MEAN)
Placebo ControlExplicit Memory Performance1.16 units on a scale
PropofolExplicit Memory Performance.51 units on a scale
DexmedetomidineExplicit Memory Performance1.04 units on a scale
FentanylExplicit Memory Performance.98 units on a scale
Secondary

Brain Activation in the Hippocampus for Successful Memory Formation: Placebo Condition Minus Drug Condition

The Z-score is calculated by linear regression of the task timing against the MRI signal time-course (MRI data is in arbitrary units with no maximum or minimum) at each voxel (single data point in brain). The outcome is listed for the hippocampus, but similar scores are calculated throughout the brain. Z-score of 0 indicates no task-related changes. Z-scores further from zero indicate a larger difference in brain activity, with positive values indicating decreases under the drug condition, while negative Z-scores indicate increases under drug, compared to control. This outcome is reported as a number, as it is calculated using all the data across subjects combined into one statistical measure for the overall strength of difference in MRI signal change between two groups of data. Dispersion measures cannot be calculated for the summary Z-score.

Time frame: Immediately after each experimental item

ArmMeasureValue (NUMBER)
Placebo ControlBrain Activation in the Hippocampus for Successful Memory Formation: Placebo Condition Minus Drug Condition3.8 Z-score for difference
PropofolBrain Activation in the Hippocampus for Successful Memory Formation: Placebo Condition Minus Drug Condition-4.9 Z-score for difference
DexmedetomidineBrain Activation in the Hippocampus for Successful Memory Formation: Placebo Condition Minus Drug Condition-5.0 Z-score for difference
Secondary

Heart Rate Response

Heart rate changes (measured by electrocardiogram, EKG) were planned to be determined following experimental stimuli that delivered as part of the experiment. A 1-6 second window of physiologic data will be analyzed for changes in the peak of the EKG response (R-wave), allowing calculation of instantaneous heart rate. Increases in heart rate are well-known to correlate to sympathetic nervous system activity increases.

Time frame: Immediately after each experimental item

Population: Acquisition of EKG data was not possible in the scanner, due to interference from the magnetic field. This is why the outcome cannot be reported.

Secondary

Skin Response

Electrodermal activity (galvanic skin) response was planned to be determined following experimental stimuli that delivered as part of the experiment. A 1-6 second window of physiologic data will be analyzed for changes in electrodermal activity, measured from the palm of subjects' hand. this well-established measure indicates sweat gland activity and is correlated to sympathetic nervous system activity increases.

Time frame: Immediately after each experimental item

Population: Acquisition of skin conductance data was not possible in the scanner, due to interference from the magnetic field. This is why the outcome cannot be reported.

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026